摘要
过敏反应是头孢曲松钠的主要不良反应,而严重过敏反应可导致患者过敏性休克甚至死亡。药品不良反应监测显示,在报告的头孢曲松钠不良反应中,过敏反应的报告数位列第一。文献研究结果也显示,由头孢曲松钠引起的过敏性休克及致死病例数双双位列头孢菌素类抗生素的首位。目前国内已有制药企业将"给药前需进行皮肤过敏试验"写入头孢曲松钠的说明书。为有效预防头孢曲松钠过敏反应的发生,除推行规范的皮肤过敏试验外,还应按说明书要求严格控制头孢曲松钠的贮藏温度。
Allergy is the main adverse drug reaction （ADR） of ceftriaxone sodium, and the severe allergic reaction can result in allergic shock and even death. Monitoring for ADR showed that the incidence of allergic reactions ranked ifrst in all ADR of ceftriaxone sodium. The results from literature investigation also showed that the cases of allergic shock and death caused by ceftriaxone sodium both ranked ifrst in all cephalosporins. Now dermal sensitivity test （DST） has been demanded in some package inserts of ceftriaxone sodium by some pharmaceutical companies in China. In order to effectively prevent the occurrence of allergic reactions resulting from ceftriaxone sodium, the temperature for ceftriaxone sodium storage should be strictly controlled according to the package insert besides the full implement of standard DST.
出处
《上海医药》
CAS
2014年第7期4-8,共5页
Shanghai Medical & Pharmaceutical Journal
